Society News2021-08-27T10:57:04+00:00
22November, 2022

Will N-of-1 Drugs Play a Role in the Future of Medicine?

November 22nd, 2022|Categories: Featured Perspectives On Current Science|

Throughout the millennia, anyone who had anything beyond a simple illness could only do their best to ease the pain and petition whatever deities their culture believed in. Then, in the past few centuries, medicine and science have advanced to the point that many illnesses and diseases can be successfully treated. Unfortunately, rare diseases have not been given the ...

9November, 2022

Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues

November 9th, 2022|Categories: Featured Perspectives On Current Science|

In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). The drug, ABX1100, is designed to treat the debilitating genetic condition called Pompe disease. What makes ...

3November, 2022

Reflections following the 20th annual meeting on oligonucleotide therapeutics

November 3rd, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About 50 years ago, several scientists independently conceived of the idea of blocking gene expression with synthetic DNA or RNA “antisense” oligonucleotides (ASO) designed to bind specifically to complementary “sense” mRNA ...

27October, 2022

2022 Annual Meeting Highlights

October 27th, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

We truly enjoyed meeting in person again this year and hope those of you who were able to attend enjoyed it as well. We want to share interesting highlights from a few of the sessions. If you missed a talk or want to go back and review any of the speakers, sessions, or posters, they all will remain online ...

23September, 2022

Eplontersen May Soon Provide Another Safe, Effective Treatment for People Diagnosed with ATTR

September 23rd, 2022|Categories: Featured Perspectives On Current Science, Perspectives on Current Science|

People who have been diagnosed with hereditary transthyretin amyloidosis (ATTRv) may soon have the option of choosing another safe, effective therapy, one that significantly improves quality of life, according to patients who received it in the clinical trial. ATTRv is a progressive, debilitating, fatal disease in which amyloids form when abnormal transthyretin proteins are produced and misfold. The ...

8September, 2022

The Personal Journey of Stanley Crooke, the Creation and Development of Ionis, and Beyond

September 8th, 2022|Categories: Perspectives on Current Science|

More than 30 years ago, Dr. Stanley Crooke founded Ionis Pharmaceuticals — a biotech company that helped pioneer the now successful technology of antisense oligonucleotides (ASO) despite overwhelming challenges and widespread disbelief. After stepping down last year as the company's CEO, Crooke recently published a perspective of his journey in creating Ionis. But to understand what drove Crooke to ...

Go to Top